bioAffinity Technologies, Inc. Common Stock
BIAF XNAS
$3.96
+0.00 (+0.00%)
▲
15-min delayed
Open
N/A
High
N/A
Low
N/A
Volume
N/A
Market Cap
$21.28M
About bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| TTM 2025 | $6.16M | $-14,909,754 | $-8.66 |
| FY 2025 | $6.16M | $-14,909,754 | $-8.66 |
| Q3 2025 | $1.45M | $-5,051,084 | $-4.74 |
| Q2 2025 | $1.27M | $-4,060,787 | $-0.17 |
Earnings & Analyst Ratings
Next Earnings:
Wed, May 13, 2026
Calendar →
TickerDaily Coverage
Why Is bioAffinity Technologies, Inc. (BIAF) Stock Up 50.7% Today?
Penny Stocks
Marcus Rivera · Mar 17, 2026
bioAffinity Technologies (BIAF) stock exploded 50.7% higher Tuesday, March 17, 2026, hitting $2.84...
Why Is bioAffinity Technologies, Inc. Common Stock (BIAF) Stock Up 94.3% Today?
Penny Stocks
Marcus Rivera · Mar 13, 2026
bioAffinity Technologies (BIAF) stock exploded 94.3% Friday, jumping from $1.07 to $2.14 on massive...
Stock Market Today: Big Tech Mixed as Penny Stocks Surge 80%+ in Weekly Frenzy
Market News
David Brooks · Mar 13, 2026
The stock market today showed resilience despite mixed signals from growth stocks, while a...
View All Coverage →
Get BIAF Alerts
Stay ahead with breaking news, price alerts, and expert analysis on bioAffinity Technologies, Inc. Common Stock.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.